Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
A team of scientists led by the Department of Energy’s Oak Ridge National Laboratory designed a molecule that disrupts the infection mechanism of the SARS-CoV-2 coronavirus and could be used to develop new treatments for COVID-19 and other viral diseases.
Five technologies invented by scientists at the Department of Energy’s Oak Ridge National Laboratory have been selected for targeted investment through ORNL’s Technology Innovation Program.
Oak Ridge National Laboratory researchers have retrofitted a commercial refrigeration container designed to ensure COVID-19 vaccines remain at ultra-low temperatures during long transport and while locally stored.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.
When Kashif Nawaz looks at a satellite map of the U.S., he sees millions of buildings that could hold a potential solution for the capture of carbon dioxide, a plentiful gas that can be harmful when excessive amounts are released into the atmosphere, raising the Earth’s temperature.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
Three technologies developed by ORNL researchers have won National Technology Transfer Awards from the Federal Laboratory Consortium. One of the awards went to a team that adapted melt-blowing capabilities at DOE’s Carbon Fiber Technology Facility to enable the production of filter material for N95 masks in the fight against COVID-19.
The annual Director's Awards recognized four individuals and teams including awards for leadership in quantum simulation development and application on high-performance computing platforms, and revolutionary advancements in the area of microbial
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.